EUVIMEDEUVIMED entdecken
Übersichtsarbeit

How I manage mantle cell lymphoma: indolent versus aggressive disease

Matthew R Wilson iD, Aisling Barrett, Chan Yoon Cheah iD, Toby A Eyre iD

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18697 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Matthew R Wilson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Beatson West of Scotland Cancer Centre, Glasgow, UK. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Antineoplastic Agents, Lymphoma, B-Cell. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 81 Literaturangaben. Gefördert von: Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mantle cell lymphoma (MCL) is a mature B‐cell lymphoma with a variable clinical course and historically poor prognosis. Management is challenging in part due to the heterogeneity of the disease course, with indolent and aggressive subtypes now well recognised. Indolent MCL is often characterised by a leukaemic presentation, SOX11 negativity and low proliferation index (Ki‐67). Aggressive MCL is characterised by rapid onset widespread lymphadenopathy, extra‐nodal involvement, blastoid or pleomorphic histology and high Ki‐67. Tumour protein p53 ( TP53 ) aberrations in aggressive MCL are recognised with clear negative impact on survival. Until recently, trials have not addressed these specific subtypes separately. With the increasing availability of targeted novel agents and cellular therapies, the treatment landscape is constantly evolving. In this review, we describe the clinical presentation, biological factors, and specific management considerations of both indolent and aggressive MCL and discuss current and potential future evidence which may help move to a more personalised approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellAntineoplastic AgentsLymphoma, B-CellAdultHumansKi-67 AntigenDisease Progression

Stichwörter der Autor:innen

chemotherapylymphomaslymphoproliferative diseasenon-Hodgkin lymphoma

Substanzen

Ki-67 AntigenAntineoplastic Agents

Autor:innen und Institutionen

  • Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Haematology and Cancer Centre, Oxford University Hospitals National Health Service (NHS) Foundation Trust, Oxford, UK.
  • Department of Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
  • Division of Internal Medicine, University of Western Australia, Perth, Australia.

ORCID-Profile: Matthew R Wilson, Chan Yoon Cheah, Toby A Eyre

Förderung

  • Department of Health

Zitieren

APA

Wilson, M. R., Barrett, A., Cheah, C. Y., & Eyre, T. A. (2023). How I manage mantle cell lymphoma: indolent versus aggressive disease. British Journal of Haematology. https://doi.org/10.1111/bjh.18697

Vancouver

Wilson MR, Barrett A, Cheah CY, Eyre TA. How I manage mantle cell lymphoma: indolent versus aggressive disease. British Journal of Haematology. 2023. doi:10.1111/bjh.18697

BibTeX
@article{Wilson2023,
  author = {Wilson, Matthew R and Barrett, Aisling and Cheah, Chan Yoon and Eyre, Toby A},
  title = {How I manage mantle cell lymphoma: indolent versus aggressive disease},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18697}
}
Kostenlos starten →